



NEW SIMPLE REVENUE STREAM IMMEDIATELY

This turnkey model provides real opportunity for dermatology practices. SkinCure Oncology takes the risk, and the practice enjoys incremental revenue from month one!

ILLUSTRATIVE PROCESS TIMELINE*

DAYS FROM CONTRACT SIGNING: 30 60 90 120 150

The Sensus unit(s) are ordered.

Application to the regulating state agency for a registration and shielding approval.

Buildout of the suite will be completed without disruption to the clinic over a weekend.

A radiation therapist assigned to the customer's location will be secured within

Acceptance and commissioning (1 week after installation)

Customer training and certification (1-2 weeks after installation)

CREGER00053

Go-Live: First Patient Treatment (135 days from contract signing)

- * In certain cases, SkinCure Oncology can accelerate these timelines and shorten the go-live period to as little as 45 days from signing.
(contingent upon machine availability, state regulations, etc.)

"Joining the SkinCure Oncology team has really opened my eyes to t
optimize patient satisfaction and outcomes. As a Mohs surgeon, I know
would prefer a non-invasive alternative. The support staff that SkinCure
work with, and has improved access to care

Dr. Ladd Jr.




200 S. Frontage Rd., Suite 200, Burr Ridge, IL 60527
 630-601-4060 (tel:630-601-4060) info@skincureoncology.com
 Media Contact | Kelly Klopp | 312-755-3521 | kk@respublicagroup.com

f (<https://www.facebook.com/skincureoncology>) 

(<https://www.youtube.com/channel/UCrQYQX2Ep4mzA97r-otLZPg>) **in**

(<https://www.linkedin.com/company/skincure-oncology/>) 

(<https://twitter.com/SkinCureSRT>) 


(<https://www.instagram.com/skincureoncology>)

© 2019 SKINCUREONCOLOGY.COM


CREGER0055

OUR EXPERTISE IN CYBER SKIN CANCER TREATMENT IS NOW YOURS

The scalpel-free approach
for treating skin cancer –
“Cure without Cutting”



CREGER00056



THE FIRST NATIONALLY FOCUSED COMPANY TO DEVELOP AND SUPPORT A NETWORK OF DERMATOLOGY-BASED, SRT SKIN CANCER TREATMENT PRACTICES

SkinCure Oncology helps practices capitalize on new technology to treat the ever-increasing incidence of skin cancer, which is expanding with the aging U.S. population. The company was created in 2016 by the founders of Accelitech and Dermatologist/Mohs surgeon Dr. Daniel J. Ladd. Until recently the primary intervention for non-melanoma skin cancer treatment centered on surgical interventions, with Mohs micrographic surgery existing as the "gold standard." However, a new non-surgical alternative now exists, and the numbers of Mohs surgeons are limited. The goal for SkinCure Oncology is to provide better access to this new non-surgical alternative for certain patients, including those with co-morbid conditions of blood thinner maintenance and diabetic concerns. Traditional therapies are not workable for these types of patients. Upon researching the problem, Accelitech and Dr. Ladd realized that there exists a genuine need for non-surgical alternatives and better access to care. **CREGER000057**



Implement and expand proven treatment protocols developed in the radiotherapy arena in Dermatology offices

Educate and involve Dermatologists (the real skin cancer experts) in the use of SRT as an alternative to traditional surgical interventions for their patients

Use the most recent advances in computerized image-guided radiotherapy for non-melanoma skin cancers

Be known as the leader in SRT skin cancer solutions

LEADERSHIP TEAM / ADVISORS



Kerwin J. Brandt




Steven L. Scott



Dr. Daniel

CREGER00059

AFFILIATED DERMATOLOGY PRACTICES



Tru-Skin Dermatology
(<http://www.tru-skin.com>)

Heights Dermatology
(<http://heightsskin.com>)


Bayside Dermatology
(<http://baysideskin.com>)

"The SkinCure Oncology team has exceeded my expectations in every way
I have been able to expand our treatment protocols to better serve our current patients."

CREGER00060

Dr. Brown

"We're an extremely patient-focused group. Recommending the optimal :
is our number one priority. Based on our initial interactions with SkinCu
we're expanding the SDT program to additir



200 S. Frontage Rd., Suite 200, Burr Ridge, IL 60527
630-601-4060 (tel:630-601-4060) info@skincureoncology.com
Media Contact | Kelly Klopp | 312-755-3521 | kk@respublicagroup.com

CREGER0061

 (<https://www.facebook.com/skincureoncology>) 

(<https://www.youtube.com/channel/UCrQYQX2Ep4mzA97r-otLZPg>) 

(<https://www.linkedin.com/company/skincure-oncology/>) 

(<https://twitter.com/SkinCureSRT>) 


(<https://www.instagram.com/skincureoncology>)

© 2019 SKINCUREONCOLOGY.COM


CREGER00062

OUR EXPERTISE IN CYBER SKIN CANCER TREATMENT IS NOW YOURS

The scalpel-free approach
for treating skin cancer –
“Cure without Cutting”



CREGER00063




THE FIRST NATIONALLY FOCUSED COMPANY TO DEVELOP AND SUPPORT A NETWORK OF DERMATOLOGY-BASED, SRT SKIN CANCER TREATMENT PRACTICES

SkinCure Oncology helps practices capitalize on new technology to treat the ever-increasing incidence of skin cancer, which is expanding with the aging U.S. population. The company was created in 2016 by the founders of Accelitech and Dermatologist/Mohs surgeon Dr. Daniel J. Ladd. Until recently the primary intervention for non-melanoma skin cancer treatment centered on surgical interventions, with Mohs micrographic surgery existing as

CREGER0064

the "gold standard." However, a new non-surgical alternative now exists, and the numbers of Mohs surgeons are limited. The goal for SkinCure Oncology is to provide better access to this new non-surgical alternative for certain patients, including those with co-morbid conditions of blood thinner maintenance and diabetic concerns. Traditional therapies are not workable for these types of patients. Upon researching the problem, Accelitech and Dr. Ladd realized that there exists a genuine need for non-surgical alternatives and better access to care.



Implement and expand proven treatment protocols developed in the radiotherapy arena in Dermatology offices

Educate and involve Dermatologists (the real skin cancer experts) in the use of SRT as an alternative to traditional surgical interventions for their patients

Use the most recent advances in computerized image-guided radiotherapy for non-melanoma skin cancers

Be known as the leader in SRT skin cancer solutions

DEVELOPMENT EXPERTISE ()

LEADERSHIP TEAM / ADVISORS



Kerwin J. Brandt




Steven L. Scott

CREGER00066

DEVELOPMENT EXPERTISE ()

AFFILIATED
DERMATOLOGY
PRACTICES




Tru-Skin Dermatology
(<http://www.tru-skin.com>)

Heights Dermatology
(<http://heightsskin.com>)

B:

CREGER0067

DEVELOPMENT EXPERTISE ()



200 S. Frontage Rd., Suite 200, Burr Ridge, IL 60527 630-601-4060 (tel:630-601-4060) info@skincureoncology.com

Media Contact | Kelly Klopp | 312-755-3521 | kk@respublicagroup.com

f (<https://www.facebook.com/skincureoncology>) **YouTube**
(<https://www.youtube.com/channel/UCrQYQX2Ep4mzA97rotLZPg>) **in** ([https://www.linkedin.com/company/skincure-](https://www.linkedin.com/company/skincureoncology/)
[oncology/](https://www.linkedin.com/company/skincureoncology/)) **Twitter** (<https://twitter.com/SkinCureSRT>) **Instagram**
(<https://www.instagram.com/skincureoncology>)

© 2019 SKINCUREONCOLOGY.COM

CREGER00068


A STEP AHEAD OF THE CHANGING ENVIRONMENT IN DERMATOLOGY



THE FACTS



CREGER00069



TECHNOLOGY INNOVATION ()

Skin cancer incidence is continuing to increase as the population ages
Dermatologists and Mohs surgeons are facing increasing competition
Reimbursement cuts continue to squeeze margins and add pressure on Dermatology practices and physician compensation


Dermatology practices and physicians are looking for new ways to:

- Improve patient satisfaction and outcomes

- Differentiate within their markets

- Increase practice and physician revenue and income

- Maintain a viable, independent practice



CREGER0070

TECHNOLOGY INNOVATION () SRT IS REVOLUTIONIZING SKIN CANCER TREATMENT IN A DERMATOLOGICAL SETTING

Superficial Radiation Therapy (SRT) has evolved into multi-energy offerings with ultrasound-based, image-guided field placement and tumor volume analysis.

SRT is faster. Treatments are completed in as little as one month over 20 fractions—over 40% fewer treatments than in cancer centers.


Treatments are well tolerated by patients. There is no pain, scarring or the need to stop blood thinners. Daily doses range from 250–280cGy, which is very well tolerated, including in the lower extremities.

Outstanding outcomes. Local control rates for non-melanoma skin cancers are comparable with Mohs micrographic surgery, long considered the “gold standard” in the industry. SRT has the added value of superior cosmesis, no requirement for halting blood thinners, better outcomes for lower extremities, and little to no disruption in daily activities.

Patients are seeking out non-invasive solutions. Patients have grown weary of ongoing surgical interventions, are becoming well educated about options, and are looking for alternatives.



CREGER00071




TECHNOLOGY INNOVATION ()

OVER 95%+
CURE RATE FOR
NON-MELANOMA
SKIN CANCER

CREGER00072

TECHNOLOGY INNOVATION ()



CREGER0073

HIGH-FREQUENCY ULTRASOUND IMAGE GUIDANCE SYSTEM WITH ULTRA IMPRESSIVE ENHANCEMENTS

The SRT-100 Vision™ has many unique features that make treatment safe, comfortable and effective for patients.

Laser Positioning System – For precise beam port positioning and repositioning on the treatment area

LesionCam™ – Provides lesion photo-registration and a video of treatment for patient records

Touch-Screen Control Console and Control Module – Facilitates the set-up, initiation, monitoring and termination of exposures

Audio/Visual Monitor – Provides constant bi-directional patient communication

Automatic Al and CU Milter magazine – Applies the correct filter to match the selected energy and beam depth

Electronic Medical Records (EMR), HL7 and PDF Record and Report Export – Organizes patient scheduling and record management to optimize workflow


Dosimetry – Record and Verify – Calculates proper dosing and measures each dose administered during treatment to ensure patient safety and optimal outcomes

RADCheck™ QC – Automatically confirms system calibration each time the system is initiated to ensure the patient is receiving the correct dose and eliminates the need for unscheduled calibrations

PATIENT OUTCOMES

BASAL CELL CARCINOMA


CREGER00074



TREATMENT FIELD




DAY OF FINAL TREATMENT




AT FOLLOW-UP

SQUAMOUS CELL CARCINOMA




DAY OF BIOPSY



PATHOLOGY



DAY OF FINAL TREATMENT



AT FOLLOW-UP


SQUAMOUS CELL CARCINOMA



TREATMENT FIELD




DAY OF FINAL TREATMENT




AT FOLLOW-UP

TECHNOLOGY INNOVATION ()



"Joining the SkinCure Oncology team has really opened my eyes to how we can optimize patient satisfaction and outcomes. As a Mohs surgeon, I would prefer a non-invasive alternative. The support staff that SkinCure works with, and has improved access to


Dr. Ladd



"We're an extremely patient-focused group. Recommending the o

CREGER0076

TECHNOLOGY INNOVATION ()



200 S. Frontage Rd., Suite 200, Burr Ridge, IL 60527 630-601-4060 (tel:630-601-4060) info@skincureoncology.com

Media Contact | Kelly Klopp | 312-755-3521 | kk@respublicagroup.com

f (<https://www.facebook.com/skincureoncology>) 
(<https://www.youtube.com/channel/UCrQYQX2Ep4mzA97rotLZPg>) **in** (<https://www.linkedin.com/company/skincureoncology/>)  (<https://twitter.com/SkinCureSRT>) 
(<https://www.instagram.com/skincureoncology>)

© 2019 SKINCUREONCOLOGY.COM

CREGER00077

WIN-WIN-WIN

SRT Benefits Patients, Physicians,
and Dermatology Practices

SKINCURE ONCOLOGY: THE NEW STANDARD FOCUS, COLLABORATION AND QUALITY

Current Industry Standard

- Limited experience in Dermatology using SRT treatment techniques
- Few standard protocols
- Limited oversight or QA
- Radiation oncologist not always involved (but may be required in some states)

SkinCure Oncology Standard

- Experienced Radiation Therapist at every site
- Physics calibration and review
- Standardized protocols
- Oversight and QA for all cases
- Ready access to an SRT-experienced Dermatologist

CREGER00078

TREATMENT SIMPLICITY ()

IMPROVING

PHYSICIANS AND
THEIR
DERMATOLOGY
PRACTICES
WIN

"Cure Without Cutting" option for patients

Outstanding outcomes

No referral outside of the practice

Significant incremental revenue stream

Additional time for other pursuits

Differentiation from the competition

Increase practice and physician revenue and income

Maintain a viable independent practice

CREGER0079

TREATMENT SIMPLICITY ()



**PATIENTS
WIN**

95%+ cure rates for non-melanoma skin cancer

Short treatment sessions

No anesthesia, cutting, bleeding, stitching or pain

No downtime or lifestyle restrictions


Superior cosmesis, no unsightly scarring

No need for post-treatment reconstructive surgeries




CREGER00080

TREATMENT SIMPLICITY ()



CREGER00081

TREATMENT SIMPLICITY ()



Did you know?

An estimated 700,000 cases of Squamous Cell Carcinoma (SCC) are diagnosed each year in the U.S., and incidence of the disease has increased up to 200% in the past three decades.

SRT IS AN
EXCELLENT ALTERNATIVE
TREATMENT METHOD TO SURGERY

CREGER0082

Surgery

TREATMENT SIMPLICITY ()

Limited access to surgeons

Lengthy procedure

Scarring

Return visit for closure
requiring the physician's time

Increased costs due to
plastic surgeon involvement

Painful

Requires stoppage of blood thinners

Poor healing on lower extremities

Diabetes complications

Requires the use of antibiotics

SRT Treatment

No cutting

Short procedure

No scarring

Twenty 15-minute treatment visits,
independent of the physician's time

All costs captured with single practice;
no surgeon involvement

Painless treatments

Does not require stoppage of blood thinners


Excellent healing

No diabetes complications

CREGER00083

Does not require the use of antibiotics

TREATMENT SIMPLICITY ()



Keloid Scar Treatment

There are approximately 18 million people suffering from keloid scars in the U.S., with new incidences in the hundreds of thousands per year.

Keloids typically present in patients post-piercing or surgical intervention.

Keloids are readily controlled when treated with SRT in one to five fractions immediately following excision over one to two weeks.


There is a significant opportunity for Dermatologists to gain new business through the treatment of patients with keloids originating from body piercings, surgical scars and injuries.

Reimbursement for keloid treated with SRT is generally cash-pay, and can be a significant source of revenue. Additionally, some commercial carriers reimburse for keloid treatment with SRT when the lesions are symptomatic.

CREGER00084

TREATMENT SIMPLICITY ()

REIMBURSEMENT
FOR KELOID SRT
**CAN BE A
SIGNIFICANT
REVENUE SOURCE**



CREGER0085

TREATMENT SIMPLICITY ()



200 S. Frontage Rd., Suite 200, Burr Ridge, IL 60527 630-601-4060 (tel:630-601-4060)
info@skincureoncology.com

Media Contact | Kelly Klopp | 312-755-3521 | kk@respublicagroup.com

f (<https://www.facebook.com/skincureoncology>) **YouTube**
(<https://www.youtube.com/channel/UCrQYQX2Ep4mzA97r-otLZPg>)
in (<https://www.linkedin.com/company/skincure-oncology/>) **Twitter**
(<https://twitter.com/SkinCureSRT>) **Instagram**
(<https://www.instagram.com/skincureoncology>)

© 2019 SKINCUREONCOLOGY.COM

CREGER00086

FILTER

NEWS

> All (780,278)

> Topic (891,867)

> Industry
(127,606)

> Method/Location
(661,287)

> Career Advice
(3,792)

> Employer
Insights (168)

> Therapeutic
Insights (737)

> Coronavirus
(COVID-19) News
(2,883)

SkinCure Oncology Announces Delivery of Its 46th Image Guided Superficial Radiation Device for Skin Cancer Treatment

Published: Jan 12, 2018



Jan. 11, 2018 21:05 UTC

CHICAGO--(BUSINESS WIRE)-- **SkinCure Oncology**, the world-wide leader in providing a turnkey model for the delivery of Superficial Radiation Therapy (SRT) for the treatment of non-melanoma skin cancers, today announces it has taken delivery of its 46th image guided superficial radiation therapy system. As the world-wide leader, SkinCure Oncology has partnered with quality-focused dermatologists and Mohs surgeons to bring cancer center level

CREGER00087